PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.09%
Cash & equivalents declining -9.09% while TRVN's grows 24.40%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Below half of TRVN's 24.40%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.56%
Above 1.5x TRVN's -13.22%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-10.41%
Below half of TRVN's 19.74%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-5.27%
1.25-1.5x TRVN's -4.27%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.98%
Higher Long-Term Investments Growth compared to TRVN's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
1.25-1.5x TRVN's -3.97%. Bruce Berkowitz checks if expansions surpass competitor's pace but remain justified.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Below half of TRVN's 16.15%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-5.64%
Less than half of TRVN's -38.86%. David Dodd sees a more disciplined AP approach or lower volume.
1.56%
Less than half of TRVN's -100.00%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Less than half of TRVN's 100.00%. David Dodd sees fewer expansions in other current obligations.
-5.23%
Less than half of TRVN's -24.71%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
Less than half of TRVN's 69.50%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
Less than half of TRVN's 43.01%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
≥ 1.5x TRVN's -1.41%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.89%
Below half TRVN's -63.72%. Michael Burry sees potential underperformance in building shareholder capital.
-10.20%
Below half TRVN's 16.15%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.98%
Higher Total Investments Growth compared to TRVN's zero value, indicating better performance.
-5.39%
Less than half of TRVN's 75.90%. David Dodd sees less overall debt expansion vs. competitor.
9.19%
Less than half of TRVN's 104.50%. David Dodd sees better deleveraging or stronger cash buildup than competitor.